The FDA has cleared two new drugs, tafamidis and tafamidis meglumine, for the treatment of cardiomyopathy caused by a rare disorder known as transthyretin-mediated amyloidosis (ATTR-CM).

Research out of the University of Manchester suggests Tadalafil (Cialis)—an erectile dysfunction drug that falls in the same class as Viagra—could slow and possibly reverse the progression of heart failure (HF).

Five milligrams of rivaroxaban per day added to a patient’s standard therapy for heart failure (HF) and coronary artery disease (CAD) could reduce that patient’s risk of future thromboembolic events, researchers reported in JAMA Cardiology April 24.

The same genetic variants that have been uncovered in patients with two other types of cardiomyopathy are also present in an uncommonly high proportion of people with cancer therapy-induced cardiomyopathy (CCM), researchers reported in Circulation.

Researchers at Tel Aviv University in Israel have 3D-printed what they said is the first vascularized heart using a patient’s own cells and biological materials.

A study of nearly 900,000 patients with heart failure or cardiogenic shock revealed their race, insurance coverage and ZIP code were associated with their odds of receiving a left ventricular assist device (LVAD).

Compared to warfarin, all direct oral anticoagulants (DOACs) were associated with fewer cardiovascular events including heart attacks and strokes in a study of Medicare patients with both nonvalvular atrial fibrillation and heart failure. But apixaban appeared to offer the best balance of protecting against these events while minimizing bleeding risk.

In the latest study to link influenza and cardiovascular disease, researchers found that the most severe flu seasons coincided with spikes in hospitalizations for heart failure.